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Predictors of COPD in symptomatic
smokers and ex-smokers seen
in primary care
Oliver Djurhuus Tupper1, Peter Kjeldgaard1,
Anders Løkke2 and Charlotte Suppli Ulrik1,3
Abstract
Even in subjects at high risk of chronic obstructive pulmonary disease (COPD), the diagnosis is often missed due to
lack of awareness of symptoms and risk factors. The objective of this study was to identify predictors of a diagnosis
of COPD in symptomatic current and ex-smokers seen in a primary care setting. General practitioners (n¼ 241)
consecutively recruited subjects 35 years, with tobacco exposure, at least one respiratory symptom (i.e. cough,
sputum, wheeze, dyspnoea and/or recurrent lower respiratory tract infections), and no previous diagnosis of
obstructive airways disease. Information on age, smoking status, body mass index (BMI) and dyspnoea (Medical
Research Council (MRC) dyspnoea scale) was obtained. Individuals with airway obstruction (i.e. forced expiratory
volume in 1 second (FEV1)/forced vital capacity ratio (FVC) < 0.70) at initial spirometry had a diagnostic spirometry
after administration of a bronchodilator. COPD was defined as the presence of symptoms, tobacco exposure and
persistent airflow limitation. The most prevalent symptoms were cough (72%) and dyspnoea (48%). Of 3875 (50%
females, mean age 57 years) subjects screened, 700 (18.1%) were diagnosed with COPD. Multivariate logistic
regression analysis revealed that increasing age 50–59 years (OR2.4, 95% CI 1.8–3.3), 60–69 years (OR 4.1, 95% CI
3.1–5.5),70 years (OR 5.7, 95% CI 4.2–7.8), BMI < 25 (OR 2.3, 95% CI 1.9–2.7), being current smoker (OR 1.2,
95% CI 1.01–1.5), self-reported dyspnoea (OR 1.7, 95% CI 1.4–2.0), wheeze (OR 1.9, 95% CI 1.5–2.3) and sputum
(OR 1.4, 95% CI 1.1–1.7) were associated with a significantly higher risk of being diagnosed with COPD. No
association was found between gender, cough and recurrent respiratory tract infections and a diagnosis of COPD.
Among symptomatic smokers and ex-smokers seen in primary care, self-reported sputum production, wheeze,
dyspnoea and low BMI identify a subgroup with a higher likelihood of COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death in the world.1,2 How-
ever, although awareness, treatment options and prog-
nosis of COPD have improved over recent decades,
there is still room for improvement, as screening stud-
ies have observed a very high prevalence of undiag-
nosed COPD.3–6 Even in subjects at high risk of
COPD, the diagnosis is often missed due to lack of
awareness of symptoms and risk factors.7,8 Although
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we lack conclusive evidence, a delay in diagnosis may
have a significant adverse impact on patient’s quality
of life and decline in lung function.9,10 Early diagno-
sis of COPD in current smokers is critical, as smoking
cessation is the only option to slow the otherwise
accelerated decline in lung function.4,9 Furthermore,
treatment is likely to improve functional status, qual-
ity of life and reduce symptoms, also in ex-smokers.7
The current Global Initiative for Chronic Obstructive
Lung Disease (GOLD) strategy document recommends
suspectingCOPD in patients with respiratory symptoms,
that is chronic cough, sputum production or dyspnoea,
and age over 40, a family history of COPD, tobacco
exposure or relevant occupational exposure.11 Screening
of a population, irrespective of symptoms, exposure and
risk factors have so far not been shown to be effective.12
General practitioners (GPs) have a pivotal role in
recognising and evaluating patients for possible
COPD, as they are the gatekeepers to specialised care,
and therefore take care of the initial evaluation of
most patients with both acute and chronic respiratory
symptoms. The necessary awareness and tools to sus-
pect and diagnose COPD is of utmost importance, as
patients often underreport symptoms.12,13
The present study aimed to identify predictors of
COPD in a large cohort of individuals with respiratory
symptoms and tobacco exposure and no previous
diagnosis of chronic airways disease evaluated in a
primary care setting.
Methods
Study design
GPs all over Denmark were invited to take part in the
study, and the aim was to engage at least 200 GPs (i.e.
> 5% of Danish GPs) to obtain a representative sample.
Written information about the study, together with an
invitation to participate, was distributed by the spon-
soring companies’ representatives. Each participating
GP was expected to asses at least 20 consecutive sub-
jects who attended their practice and fulfilled the cri-
teria for participation in the study (6-month study
period). Subjects included had all study-related proce-
dures performed in their own GPs practice. Observa-
tions based on the present cohort have been published
previously by Løkke et al.14 and Kjeldgaard et al.15
Material and methods
Individuals were eligible for the study provided they
fulfilled the following inclusion criteria: 1) age  35
years, 2) smoker/ex-smoker, 3)  one of the follow-
ing: dyspnoea, cough, wheeze, sputum and/or recur-
rent chest infections, and none of the exclusion
criteria: 1) inability to perform spirometry, and 2)
previous diagnosis of any chronic respiratory disease.
Information for all participants were obtained with
regard to age, gender, height, body weight, smoking
status (including daily tobacco consumption and years
of smoking), current airway symptoms (including
cough, dyspnoea, wheezing, sputum and recurrent
lower airway infections) and severity of dyspnoea
(MRC-scale).16 Spirometry was performed in accor-
dance with the guidelines from the Danish Respira-
tory Society, and included at least three forced
expiratory manoeuvres with the two highest measure-
ments of forced expiratory volume in 1 second
(FEV1) and forced vital capacity (FVC), respectively,
differing less than 5% being recorded.17
Diagnostic algorithm
Airway obstruction was defined as FEV1/FVC ratio <
0.70, in accordance with the GOLD strategy docu-
ment.7 The applied diagnostic algorithm is given in
Figure 1. All participants with airway obstruction at
initial spirometry (i.e. pre-bronchodilator (BD) spiro-
metry) had a BD reversibility test performed with 0.4
mg inhaled salbutamol (or equivalent) followed by a
spirometry 15 minutes after. A positive BD test was
defined as an increase in FEV1 > 12% and 200 ml. For
the corticosteroid reversibility test, spirometry was
repeated after 6 weeks of 1600 mg budesonide (or
equivalent) daily or 37.5 mg oral prednisolone daily
for 14 days (Figure 1). (2) Participants were diagnosed
with COPD on the basis of the combination of current
or previous tobacco exposure, respiratory symptom(s)
and post-BD FEV1/FVC ratio < 0.70, in accordance
with the GOLD COPD strategy document.7
Data handling and analysis
Questionnaires and spirometry data were entered into
a consolidated web-based database. Derived values
were automatically calculated, including number of
pack-years, body mass index (BMI), FEV1% pre-
dicted and FEV1/FVC. Statistical analyses were
performed with the software SPSS v. 24.0 (IBM).
Consultants from the sponsoring companies per-
formed quality control of the case report forms.
The analyses were limited to subjects with com-
plete data. Data were tested for normality, and non-
parametric tests for independent samples were used to
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analyse continuous data. Categorical data were ana-
lysed by the Mann-Whitney U-test. In all the statisti-
cal analyses, a two-tailed p-value of  0.05 was
considered significant. Mean values are reported with
standard deviations (SDs). Multivariate logistic
regression analysis was used to evaluate predictors
for a diagnosis of COPD and reported as odds ratios
with 95% confidence intervals and p-values.
Ethics statement
The present study was endorsed by the Danish Col-
lege of General Practitioners. The study was approved
by the Danish Data Protection Agency. This study
was a non-drug and non-interventional study, but the
National Committee on Health Research Ethics and
the Danish Medicines Agency were given all relevant
study information, although this was not mandatory.
Results
Baseline characteristics
A total of 241 GPs (approximately 7% of Danish GPs)
participated in the study.Of the 4.049 screened subjects,
3875 (95.7%; 50% females; mean age 57 years (range
35–92 years)) fulfilled the inclusion criteria and were
included in the present analysis (Tables 1 and 2).
Prevalence of respiratory symptoms and COPD
Cough (72%) was the most prevalent symptom among
the enrolled subjects, followed by dyspnoea (48%)
and sputum production (31%) (Figure 2). Of 3875
subjects screened, 700 (18.1%) were diagnosed with
COPD. There were 557 subjects with COPD that
would be classified as GOLD A or C (MRC <3) and
143 that are either GOLD B or D (MRC 3). When
classified according to level of lung function,
7 patients had very severe airflow obstruction, 89 had
Respiratory
symptom(s) &
FEV1/FVC <0,70
Bronchodilator
reversibility
test
Increase in FEV1
>500 ml
Astma or other
diagnosis
Increase in FEV1
>200-500 ml
Corticosteroid
reversibility 
test
Increase in FEV1
≥200 ml
Increase in FEV1
<200 ml
Increase in FEV1
<200ml
COPD
Figure 1. Diagnostic algorithm for participants who were
identified with airflow obstruction at the screening
spirometry.
Table 1. Baseline characteristics of the enrolled subjects
(n ¼ 3875), incl. divided according to smoking status.
All
(n ¼ 3875)
Current
smokers
(n ¼ 2390)
Ex-smokers
(n ¼ 1485)
Age (years) 57.4 (11.8) 55.6 (11.2) 60.4 (12.2)a
BMI 27.0 (5.1) 26.6 (5.1) 27.6 (4.9)
Pack-years 32.2 (22.3) 34.5 (21.3) 28.5 (23.4)a
FEV1 (%pred.) 88.6 (19.6) 87.5 (18.7) 90.5 (20.9)
a
FEV1/FVC 0.75 (0.09) 0.75 (0.09) 0.76 (0.09)
MRC score 1.7 (0.7) 1.7 (0.7) 1.8 (0.75)
All values are given as means, + the standard deviation in
parentheses.
BMI: body mass index; FEV1: forced expiratory volume in 1 sec-
ond; FVC: forced vital capacity; MRC: medical research council.
ap < 0.001, current smoker versus ex-smoker.
Table 2. Baseline characteristics of all the enrolled sub-
jects (n ¼ 3875), and divided according to COPD status.
All
(n ¼ 3875)
COPD
(n ¼ 700)
No COPD
(n ¼ 3.175)
Age (years) 57.4 (11.8) 63.0 (10.5) 56.2 (11.7)a
BMI 27.0 (5.1) 25.8 (5.1) 27.2 (5.0)a
Pack-years 32.2 (22.3) 39.7 (23.2) 30.5 (21.8)a
FEV1 (L) 2.64 (0.88) 1.90 (0.69) 2.80 (0.83)
FEV1 (%pred.) 88.6 (19.6) 71.1 (19.1) 92.5 (17.5)
FEV1/FVC 0.75 (0.09) 0.61 (0.07) 0.79 (0.06)
MRC score 1.7 (0.7) 2.0 (0.8) 1.7 (0.7)a
All values are given as means, + the standard deviation in
parentheses.
COPD: chronic obstructive pulmonary disease; BMI: body mass
index; FEV1: forced expiratory volume in 1 second; FVC: forced
vital capacity; MRC: medical research council.
ap < 0.001, COPD versus no COPD.
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severe obstruction, 376 were moderately obstructed
and 228 had mild obstruction (Table 3).
Predictors of a diagnosis of COPD
The analysis revealed that sputum, wheeze and dys-
pnoea to be significant independent predictors of
COPD, while cough and recurrent lower respiratory
tract infections (LRTI) were not found to be signifi-
cant predictors (Table 4).
If we had only enrolled individuals with sputum,
wheeze and/or dyspnoea together with a history
of smoking, we should have examined 2144 individ-
uals to find 569 new cases of COPD, meaning a
number needed to screen of 3.8. On the other hand,
this would have meant that 131 subjects with COPD
would not have been found by applying these
criteria. Of these 131 subjects, 56 had mild obstruc-
tion, 67 had moderate and 8 had severe, and 4 of
these subjects had MRC  3.
Table 3. The 700 new cases of COPD divided according to
severity of airflow obstruction.
Level of FEV1 (GOLD)
Frequency
(N ¼ 700)
Mean FEV1%
predicted
Mild, FEV1 80% 215 (30.7%) 92 (SD + 10)
Moderate,
FEV1 50% to <80%
378 (54%) 66 (SD + 8.6)
Severe,
FEV1 30% to <50%
100 (14.3%) 42 (SD + 6)
Very severe, FEV1 <30% 7 (1%) 27 (SD + 3)
GOLD: Global Initiative for Chronic Obstructive Lung Disease;
FEV1: forced expiratory volume in 1 second; FVC: forced vital
capacity.
Table 4. Risk factors for a new diagnosis of COPD among
3875 symptomatic smokers and ex-smokers.
Risk factors Odds ratio 95% CI p-Value
Age (yrs) <50 – –
50–59 2.45 1.82–3.30 <0.001
60–69 4.13 3.10–5.51 <0.001
70þ 5.73 4.20–7.80 <0.001
Gender (male) 1.17 0.98–1.41
BMI
 20
 25
>25
2.29
3.23
2.17
–
1.91–2.74
2.26–4.61
1.80–2.62
–
<0.001
<0.001
<0.001
Current smokera 1.23 1.01–1.5 0.04
Pack-years 20 – –
>20–40 1.54 1.22–1.95 <0.001
>40 2.14 1.68–2.74 <0.001
Cough 1.18 0.96–1.46 0.124
Dyspnoea 1.69 1.4–2.04 <0.001
Wheeze 1.86 1.5–2.3 <0.001
Sputum 1.37 1.13–1.65 0.001
Recurrent lower
pulmonary infection
1.19 0.91–1.57 NS
COPD: chronic obstructive pulmonary disease; BMI: body mass
index; CI: confidence interval.
P-values and 95% CIs for odds ratios were obtained by multivari-
ate logistic regression. Age (grouped in quartiles), gender, BMI,
smoking status (current smoker or ex-smoker), pack-years and
respiratory symptoms were all included in the model.
aEx-smoker set as reference.
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Figure 2. Prevalence of respiratory symptoms among patients with a confirmed diagnosis of COPD and subjects with no
obstructive airways disease. COPD: chronic obstructive pulmonary disease.
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Age was found to be the strongest predictor for
COPD with an increase in odds ratio according to
higher age group. Current smokers showed a higher
odds ratio for a diagnosis of COPD, even when the
statistical model was adjusted for pack-years. As
expected higher lifetime tobacco exposure, that is
pack-years, was associated with a COPD. Low to nor-
mal BMI was, compared to high BMI, a significant
predictor of COPD. No significant association was
found between gender and a diagnosis of COPD. The
receiver operating characteric (ROC) curves revealed
that dyspnoea, sputum and wheeze all had area under
the curve between 0.52 and 0.56, and by that have
poor value as isolated diagnostic tools (Figure 3).
The number needed to assess for this population
was 5.5 (3875/700) for a new diagnosis of COPD.
Discussion
This analysis of predictors for a diagnosis of COPD
showed that dyspnoea, sputum andwheeze together with
being a current or ex-smoker identify a subgroup of indi-
viduals at a very high risk of having undiagnosedCOPD.
Wheeze and dyspnoea were independent predictors
for COPD with the highest odds ratio among the
symptoms. This correlates well with findings in pre-
vious studies.3,6,18–20 The most recent of the GOLD
COPD strategy document does not seem to promote
wheeze as a major key indicator symptom, but as a
subsymptom of chronic cough. Our data and that of
previous studies suggest that wheeze has an equal
predictive value in line with chronic cough, dyspnoea
and chronic sputum.3,18–20
We did not find cough without sputum to be a
significant independent predictor. Another similar
study that only included current smokers found cough
without sputum not to be independently significant
for a diagnosis of COPD.21 Previous studies showing
cough to be a significant predictor of COPD either
included a small population or included never smo-
kers.3,18,19,22,23 These findings suggest that cough as a
yes/no question loses its value as a discriminatory
predictor in patients at high risk for COPD, probably
because it is a very unspecific symptom.
Dyspnoea and sputum are both symptoms that show
significant independent predictive value for COPD in
the literature.18,21–23 Our data support this. Cough with
sputum showed a higher specificity than dyspnoea,
potentially based on a broader range of differential
conditions causing dyspnoea, than sputum.
Recurrent LRTI were not shown to be significant
as a predictor, most likely because of the low preva-
lence and by that lack of statistical power. Our find-
ings correlate with the three currently externally
validated COPD questionnaires (COPD diagnostic
questionnaire, COPD Population Screener and Lung
Function Questionnaire).19,20,24 None of these ques-
tionnaires include recurrent LRTI, as it was not found
to be a sufficient prognostic factor in the context of a
questionnaire. As a single prognostic indicator though
the newest GOLD guideline revision includes LRTI
as a key indicator symptom.7
Corroborating what must now be established
knowledge, we found that increasing age was a sig-
nificant independent predictor. Increasing age showed
an approximately 150% increase in OR for every
10-year rise above 50 years. Being an active smoker
versus an ex-smoker showed a significantly increased
risk of COPD. We found a strong correlation between
BMI 25 and COPD, consistent with findings by
Price et al.25 that form the basis of the COPD diag-
nostic questionnaire. On the other hand, although
Yawn et al.,24 for the development of the lung func-
tion questionnaire, also found significant correlation
between BMI and obstructive airflow limitation,
they did not include it in the final questionnaire due
to low discriminatory power and suspected problems
with BMI calculation in a self-reported question-
naire. These findings seem to favour normal or low
BMI as a significant predictor of COPD, although its
place in opportunistic screening remains unclear.
As also pointed out by the findings in a recently
published large-scale study from the UK by Jordan
et al.,26 it is important to clarify, expand and
Figure 3. ROC curve for the symptoms that were signif-
icant predictors. Wheeze area under curve (AUC) ¼ 0.55.
Sputum AUC ¼ 0.56. Dyspnoea AUC ¼ 0.52.
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disseminate knowledge about COPD diagnosis to
allow GPs to make the best possible educated deci-
sions, not least in order to identify a higher proportion
of patients with undiagnosed COPD. Screening for
COPD with the algorithm used in the present study
provides a very reasonable number needed to screen,
considering the relatively inexpensive examination
that is spirometry, both in terms of price and time.
It allows us to find patients with significant airway
obstruction with the majority having moderate or
worse obstruction and a not insubstantial portion with
high symptom burden. The highest percentage of
newly detected COPD in the study by Jordan et al.
was 5% in the active case finding group, which is
much lower than the 18% found in the present study,
probably because only symptomatic ever smokers
were eligible for inclusion in the present study.
Furthermore, based on the findings in the present
study, if necessary, because of constraints of time or
other factors, it is possible to identify a subgroup with
a very high risk of COPD by screening only current or
ex-smokers complaining of either sputum, dyspnoea
or wheeze. However, this method does mean missing
1/5 of cases, some with more severe airflow limitation
and symptom burden. So, in accordance with previous
studies,26,27 our study supports the assumption that a
structured approach, based on risk factors and respira-
tory symptoms, to case finding is far more effective
than routine care for detecting undiagnosed cases of
COPD, although further studies are clearly needed,
also in relation to the impact on long-term outcome.
Strengths and limitations
This was a large multicentre study with consecutive
recruitment in primary care. Patients had no previous
diagnosis of obstructive airways disease and diagno-
sis was based on post-BD value, which is the current
gold standard.7
Spirometrywas carriedout by theGPsor their staff, as
they do not perform a high volume of spirometric exam-
ination and regular quality checks of the spirometric
procedures are not performed, the overall quality of spir-
ometries will not be the same as in controlled clinical
trials. However, this reflects the real-world situation, as
we want our GPs to be the frontline with regard to sus-
pecting and evaluating patients for possible COPD.
Implications and summary
Based on our results, and in line with previous studies
and current GOLD guidelines, symptoms cannot be
used to diagnose the disease without spirometry, but
used to suspect a diagnosis of COPD.3 Based on find-
ings in our study current smoking, BMI  25, age
>50, dyspnoea, cough with sputum and wheeze iden-
tify a subgroup in patients with high risk for COPD
seen in primary care, with an increased likelihood
of COPD.
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